Rhenman & Partners Asset Management AB purchased a new position in EXACT Sciences Co. (NASDAQ:EXAS) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 100,000 shares of the medical research company’s stock, valued at approximately $8,662,000. Rhenman & Partners Asset Management AB owned about 0.08% of EXACT Sciences as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. increased its position in EXACT Sciences by 2.6% in the third quarter. Vanguard Group Inc. now owns 10,498,087 shares of the medical research company’s stock worth $828,509,000 after purchasing an additional 261,239 shares during the last quarter. Vanguard Group Inc increased its position in EXACT Sciences by 2.6% in the third quarter. Vanguard Group Inc now owns 10,498,087 shares of the medical research company’s stock worth $828,509,000 after purchasing an additional 261,239 shares during the last quarter. Geode Capital Management LLC increased its position in EXACT Sciences by 6.1% in the fourth quarter. Geode Capital Management LLC now owns 1,197,840 shares of the medical research company’s stock worth $75,583,000 after purchasing an additional 69,128 shares during the last quarter. Norges Bank bought a new stake in EXACT Sciences in the fourth quarter worth $67,273,000. Finally, Baillie Gifford & Co. increased its position in EXACT Sciences by 2.3% in the fourth quarter. Baillie Gifford & Co. now owns 883,894 shares of the medical research company’s stock worth $55,774,000 after purchasing an additional 19,765 shares during the last quarter. Institutional investors own 89.84% of the company’s stock.

Several brokerages recently weighed in on EXAS. Zacks Investment Research cut shares of EXACT Sciences from a “hold” rating to a “sell” rating in a research report on Thursday, April 4th. BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a research note on Friday, March 15th. Goldman Sachs Group raised shares of EXACT Sciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $85.00 to $120.00 in a research note on Tuesday, February 26th. UBS Group set a $109.00 price objective on shares of EXACT Sciences and gave the stock a “buy” rating in a research note on Friday, February 22nd. Finally, Craig Hallum set a $95.00 price objective on shares of EXACT Sciences and gave the stock a “buy” rating in a research note on Friday, February 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $99.64.

In other news, insider Kevin T. Conroy sold 304,397 shares of the business’s stock in a transaction on Friday, January 25th. The shares were sold at an average price of $81.27, for a total transaction of $24,738,344.19. Following the completion of the sale, the insider now directly owns 1,190,408 shares of the company’s stock, valued at $96,744,458.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Scott C. Johnson sold 1,166 shares of the business’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $93.20, for a total transaction of $108,671.20. The disclosure for this sale can be found here. Insiders have sold 455,507 shares of company stock valued at $37,454,557 over the last three months. Insiders own 3.20% of the company’s stock.

NASDAQ EXAS opened at $95.15 on Thursday. The company has a quick ratio of 8.70, a current ratio of 8.99 and a debt-to-equity ratio of 1.02. The firm has a market cap of $11.97 billion, a price-to-earnings ratio of -69.96 and a beta of 1.83. EXACT Sciences Co. has a 52 week low of $40.51 and a 52 week high of $97.27.

EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Thursday, February 21st. The medical research company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.05. The company had revenue of $142.98 million during the quarter, compared to analyst estimates of $143.00 million. EXACT Sciences had a negative net margin of 38.54% and a negative return on equity of 23.58%. EXACT Sciences’s quarterly revenue was up 63.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.18) earnings per share. Analysts predict that EXACT Sciences Co. will post -1.98 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/rhenman-partners-asset-management-ab-acquires-shares-of-100000-exact-sciences-co-exas/2955295.html.

EXACT Sciences Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Further Reading: What is a back-end load?

Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.